AU2022352658A1 - Polymorphs as erbb inhibitors - Google Patents
Polymorphs as erbb inhibitors Download PDFInfo
- Publication number
- AU2022352658A1 AU2022352658A1 AU2022352658A AU2022352658A AU2022352658A1 AU 2022352658 A1 AU2022352658 A1 AU 2022352658A1 AU 2022352658 A AU2022352658 A AU 2022352658A AU 2022352658 A AU2022352658 A AU 2022352658A AU 2022352658 A1 AU2022352658 A1 AU 2022352658A1
- Authority
- AU
- Australia
- Prior art keywords
- morphic
- morphic form
- compound
- xrpd
- radiation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163246451P | 2021-09-21 | 2021-09-21 | |
| US63/246,451 | 2021-09-21 | ||
| PCT/US2022/044232 WO2023049168A1 (en) | 2021-09-21 | 2022-09-21 | Polymorphs as erbb inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022352658A1 true AU2022352658A1 (en) | 2024-03-21 |
Family
ID=83691602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022352658A Pending AU2022352658A1 (en) | 2021-09-21 | 2022-09-21 | Polymorphs as erbb inhibitors |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240425492A1 (https=) |
| EP (1) | EP4405350A1 (https=) |
| JP (1) | JP2024534517A (https=) |
| KR (1) | KR20240099193A9 (https=) |
| CN (1) | CN119110799A (https=) |
| AU (1) | AU2022352658A1 (https=) |
| CA (1) | CA3231697A1 (https=) |
| IL (1) | IL311354A (https=) |
| MX (1) | MX2024003475A (https=) |
| WO (1) | WO2023049168A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020328598A1 (en) | 2019-08-15 | 2022-03-03 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
| CN120769850A (zh) * | 2023-03-02 | 2025-10-10 | 江苏康缘药业股份有限公司 | 一种炔基取代的喹唑啉化合物的晶型、其制备方法和应用 |
| WO2025038731A1 (en) * | 2023-08-15 | 2025-02-20 | Black Diamond Therapeutics, Inc. | Method of treating cancers with alkyne substituted quinazoline derivatives |
| WO2025137424A1 (en) * | 2023-12-21 | 2025-06-26 | Black Diamond Therapeutics, Inc. | Solid forms of an erbb inhibitor |
| WO2025137421A1 (en) * | 2023-12-21 | 2025-06-26 | Black Diamond Therapeutics, Inc. | Compositions comprising alkyne substituted quinazoline derivatives and related uses |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020328598A1 (en) * | 2019-08-15 | 2022-03-03 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
| US20240075042A1 (en) * | 2020-11-02 | 2024-03-07 | Black Diamond Therapeutics, Inc. | Method of treating cancers with alkyne substituted quinazoline derivatives |
-
2022
- 2022-09-21 CA CA3231697A patent/CA3231697A1/en active Pending
- 2022-09-21 MX MX2024003475A patent/MX2024003475A/es unknown
- 2022-09-21 AU AU2022352658A patent/AU2022352658A1/en active Pending
- 2022-09-21 CN CN202280075401.6A patent/CN119110799A/zh active Pending
- 2022-09-21 WO PCT/US2022/044232 patent/WO2023049168A1/en not_active Ceased
- 2022-09-21 EP EP22789775.8A patent/EP4405350A1/en active Pending
- 2022-09-21 JP JP2024517482A patent/JP2024534517A/ja active Pending
- 2022-09-21 IL IL311354A patent/IL311354A/en unknown
- 2022-09-21 KR KR1020247013097A patent/KR20240099193A9/ko active Pending
- 2022-09-21 US US18/693,733 patent/US20240425492A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240099193A9 (ko) | 2025-12-10 |
| EP4405350A1 (en) | 2024-07-31 |
| IL311354A (en) | 2024-05-01 |
| US20240425492A1 (en) | 2024-12-26 |
| JP2024534517A (ja) | 2024-09-20 |
| KR20240099193A (ko) | 2024-06-28 |
| CA3231697A1 (en) | 2023-03-30 |
| MX2024003475A (es) | 2024-04-05 |
| CN119110799A (zh) | 2024-12-10 |
| WO2023049168A1 (en) | 2023-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240425492A1 (en) | Polymorphs as erbb inhibitors | |
| US12152034B2 (en) | FGFR inhibitors and methods of making and using the same | |
| ES2685819T3 (es) | Formas mórficas de ésteres de hexadeciloxipropil-fosfonato | |
| EP4234547A2 (en) | Pharmaceutical salts of pyrimidine derivatives and method of treating disorders | |
| AU2022201947B2 (en) | Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds | |
| US11654144B2 (en) | Crystalline forms of 5-bromo-2,6-di(1H-pyrazol-1- yl)pyrimidin-4-amine and new salts | |
| EP4438613A1 (en) | Mono-p-toluenesulfonate of axl kinase inhibitor and crystal form thereof | |
| RS67641B1 (sr) | Kristalni oblici derivata hinazolina, njihova priprema, kompozicija i upotreba | |
| WO2025038731A1 (en) | Method of treating cancers with alkyne substituted quinazoline derivatives | |
| CN114728875A (zh) | 金属盐及其用途 | |
| WO2025137424A1 (en) | Solid forms of an erbb inhibitor | |
| CA3246202A1 (en) | CRYSTALLINE FORMS AND SALTS OF A PI3K INHIBITOR AND THEIR PROCESSES OF MANUFACTURE AND USE | |
| WO2025226822A2 (en) | Forms and salts of 6-aza-quinoline derivatives and related uses | |
| WO2025117550A1 (en) | Solid state forms of a quinoxaline derivative useful in the treatment of cancer | |
| WO2025128831A1 (en) | Combinations comprising alkyne substituted quinazoline derivatives and their use in the treatment of cancer | |
| WO2025137421A1 (en) | Compositions comprising alkyne substituted quinazoline derivatives and related uses | |
| HK40077267A (en) | Metal salts and uses thereof | |
| HK40079038A (en) | Method of preparing solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds | |
| JP2022504259A (ja) | Ｎ－（４－フルオロ－３－（６－（３－メチルピリジン－２－イル）－［１，２，４］トリアゾロ［１，５－ａ］ピリミジン－２－イル）フェニル）－２，４－ジメチルオキサゾール－５－カルボキサミドの固体形態 | |
| HK1234747B (zh) | 取代的咪唑并吡啶基-氨基吡啶化合物的盐和多晶型 |